clinical use of the combination chemotherapy with fosfomycin and dibekacin was thought to be effective and safe for patients with complicated urinary tract infections , because the combination acts not only synergistically , but also because fosfomycin acts to protect against the nephrotoxicity induced by dibekacin .
C0042029
urinary tract infections
C0016610
fosfomycin